Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2010 - 2026)

Pacira BioSciences' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $21.3 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 0.77% year-over-year to $21.3 million in Q1 2026; TTM through Mar 2026 was $91.2 million, a 11.85% increase from a year earlier, with the FY2025 full-year figure at $91.0 million, up 15.53% from the prior year.
• Depreciation & Amortization (CF) was little changed at $21.3 million in Q1 2026 per PCRX's latest filing, from $21.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $30.4 million in Q4 2022 and bottomed at $18.4 million in Q1 2024.
• The 5-year median for Depreciation & Amortization (CF) is $20.3 million (2024), against an average of $21.1 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 326.06% in 2022 and tumbled 39.21% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $30.4 million in 2022, then tumbled by 39.21% to $18.5 million in 2023, then grew by 14.92% to $21.2 million in 2024, then grew by 0.47% to $21.3 million in 2025, then slipped by 0.05% to $21.3 million in 2026.
• Per Business Quant, the three latest PCRX Depreciation & Amortization (CF) figures stand at $21.3 million (Q1 2026), $21.3 million (Q4 2025), and $21.2 million (Q3 2025).